Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipients

Phase 3

Completed

• Conditions: humoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromised; Immunogenicity of the vaccineEffectiveness of the vaccine

• Registration Number: TCTR20220511002
• Lead Sponsor: ational Council Researach of Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-11
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients were all recruited from the previous studies (CVIM1, CVIM2, CVIM3 and CVIM 4)

Exclusion Criteria

Those who declined to participate in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunogenecity at 6 months after vaccination Humoral and cell-mediated immunity

Secondary Outcome Measures

Name	Time	Method
Effectiveness within 6 months Rate of COVID-19 diagnosis